Conventional dose therapy in MCL
| Phase . | Chemotherapy . | N . | Age (median) . | OR (CR) % . | Median PFS (months) . | Overall survival . | Reference . |
|---|---|---|---|---|---|---|---|
| III (randomized) | R-CHOP | 112 | 61 yr | 94 (34) | 21 (TTF) | NA | 25 |
| vs | vs | vs | vs | ||||
| CHOP | 75 (7) | 14 (TTF) | 2 yr 76% | ||||
| III (randomized) | R-CHOP | 485 | 70 yr | After induction 86 (34) | 28 (TTF) | After maintenance 4 yr 62% | 28 |
| vs | vs | vs | vs | ||||
| R-FC | 78 (40) | 26 (TTF) | 4 yr 47% | ||||
| III (randomized) | R-CHOP | 94 | 70 yr | 91 (30) | 22 | NA | 29 |
| vs | vs | vs | |||||
| R-B | 93 (40) | 35 | |||||
| III (randomized) | R-CHOP/CVP | 74 | 60 yr | 85 (27) | NA | NA | 30 |
| vs | vs | ||||||
| R-B | 94 (50) | ||||||
| II | R-Cbl | 20 | 64 yr | 95 (90) | 84% 3 yr | 3 yr 95% | 33 |
| II | R-Cbl | 14 | 63 yr | 64 (36) | 15 | 26 | 80 |
| II | R-CDA | 29 | 70 yr | 66 (52) | 43% 2 yr | NA | 34 |
| Phase . | Chemotherapy . | N . | Age (median) . | OR (CR) % . | Median PFS (months) . | Overall survival . | Reference . |
|---|---|---|---|---|---|---|---|
| III (randomized) | R-CHOP | 112 | 61 yr | 94 (34) | 21 (TTF) | NA | 25 |
| vs | vs | vs | vs | ||||
| CHOP | 75 (7) | 14 (TTF) | 2 yr 76% | ||||
| III (randomized) | R-CHOP | 485 | 70 yr | After induction 86 (34) | 28 (TTF) | After maintenance 4 yr 62% | 28 |
| vs | vs | vs | vs | ||||
| R-FC | 78 (40) | 26 (TTF) | 4 yr 47% | ||||
| III (randomized) | R-CHOP | 94 | 70 yr | 91 (30) | 22 | NA | 29 |
| vs | vs | vs | |||||
| R-B | 93 (40) | 35 | |||||
| III (randomized) | R-CHOP/CVP | 74 | 60 yr | 85 (27) | NA | NA | 30 |
| vs | vs | ||||||
| R-B | 94 (50) | ||||||
| II | R-Cbl | 20 | 64 yr | 95 (90) | 84% 3 yr | 3 yr 95% | 33 |
| II | R-Cbl | 14 | 63 yr | 64 (36) | 15 | 26 | 80 |
| II | R-CDA | 29 | 70 yr | 66 (52) | 43% 2 yr | NA | 34 |
Cbl, chlorambucil; CDA, cladribine; N, number; NA, not available; R-Cbl, rituximab plus chlorambucil; R-CDA, rituximab plus cladribine; TTF, time to treatment failure.